Clinical Trial Update: Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the myeloperoxidase inhibitor A_Zeneca in heart failure with preserved ejection fraction has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• A_Zeneca

Snippet

Sponsor: Mayo Clinic | Conditions: Heart Failure | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-08